AB Science announces that it has received the first authorization to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in ALS
PRESS RELEASE AB SCIENCE ANNOUNCES THAT IT HAS RECEIVED THE FIRST AUTHORIZATION TO RESUME PATIENT…